Latest Parkinson's disease Stories
More than 10,000 Walkers Make Every Step Count in Raising Funds and Awareness for Parkinson's KINGSTON, N.J., May 21, 2013 /PRNewswire-USNewswire/ -- The Parkinson Alliance proudly announced today that the 19th Parkinson's Unity Walk held on Saturday, April 27, 2013 in New York City's Central Park, has thus far raised more than $1.6 million and united more than 10,000 walkers in raising awareness for Parkinson's disease and to support research for better treatments, and hopefully...
Clinical Data on CERE-120 (AAV-NRTN) Presented at the 16th Annual Meeting of the American Society of Gene and Cellular Therapy (ASGCT) SAN DIEGO, May 21, 2013 /PRNewswire/ -- Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin). CERE-120 is a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. This exploratory...
VALLEY VIEW, Ohio, May 15, 2013 /PRNewswire/ -- Great Lakes NeuroTechnologies announced today the product launch of Kinesia ProView(TM) [ http://www.glneurotech.com/kinesia/proview/index.php ] to visualize motor symptom severity response during programming of deep brain stimulation (DBS) for Parkinson's disease. Kinesia ProView provides a standardized platform to quantitatively assess how symptoms such as tremor, bradykinesia, and dyskinesias change in response to specific DBS...
--Recipients of $1.7 Million Award from Patient-Centered Outcomes Research Institute-- MIAMI, May 13, 2013 /PRNewswire-USNewswire/ -- The Patient-Centered Outcomes Research Institute (PCORI) has approved a research award to the National Parkinson Foundation (NPF) and Johns Hopkins University to deliver telemedicine care to people with Parkinson's disease in their homes. E. Ray Dorsey, MD, Director, Johns Hopkins Parkinson's Disease and Movement Disorders Center is the lead...
Researchers at Georgetown University Medical Center have used tiny doses of a leukemia drug to halt accumulation of toxic proteins linked to Parkinson's disease in the brains of mice. This finding provides the basis to plan a clinical trial in humans to study the effects. They say their study, published online May 10 in Human Molecular Genetics, offers a unique and exciting strategy to treat neurodegenerative diseases that feature abnormal buildup of proteins in Parkinson's disease,...
NEW YORK, May 8, 2013 /PRNewswire-USNewswire/ -- The Michael J. Fox Foundation (MJFF) is today announcing the launch of three new funding programs focused on driving research toward transformative treatments and a cure for Parkinson's disease (PD). Two programs will promote critical work on the promising therapeutic targets LRRK2 and Parkin. A third program allows researchers to propose developing biomarkers of cognitive impairment in PD. The new funding opportunities are open to...
Weill Cornell Medical School chooses MediGait to provide improvement in balance and overcoming the debilitating fear of falling for people with Parkinson's disease, Multiple Sclerosis and the elderly. Haifa, Israel (PRWEB) May 06, 2013 The numbers are shocking: one in three adults over the age of 65 will fall and hurt themselves this year. According to the CDC, “falls are the leading cause of injury death among the elderly. They are also the most common cause of nonfatal injuries...
CARDIFF, Calif., May 6, 2013 /PRNewswire/ -- NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's. "The current therapeutic options for PD are limited in scope and duration of utility. Motoric symptoms can be attenuated, but over time, there is a price to be paid, as L-dopa related dyskinesias eventually emerge for many...
Brett Smith for redOrbit.com - Your Universe Online By working with mouse and fruit fly hearts, researchers at Washington University (WUSTL) School of Medicine, St. Louis identified a key protein that has a connection with Parkinson’s disease and heart failure. According to a new report in the journal Science, a protein known as mitofusin 2 (Mfn2) is the missing link in the chain-reaction that starts with mitochondrial dysfunction and ends with Parkinson’s disease or heart failure,...
A protein known to be a key player in the development of Parkinson's disease is able to enter and harm cells in the same way that viruses do, according to a Loyola University Chicago Stritch School of Medicine study. The protein is called alpha-synuclein. The study shows how, once inside a neuron, alpha synuclein breaks out of lysosomes, the digestive compartments of the cell. This is similar to how a cold virus enters a cell during infection. The finding eventually could lead to the...
